Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

- September 18th, 2018

Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, “Emblem”).

Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, “Emblem”).

Dissolution testing conducted by Emblem and Canntab’s research and development teams indicated that the Extended Release Tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, the Company will now begin manufacturing pivotal batches of these tablets for pharmacokinetic and clinical testing. Under the license agreement between Canntab and Emblem, development and initial production will take place at Emblem’s Paris, Ontario facility. Emblem will continue to advocate Health Canada for the approval of this and other advanced formulations of cannabinoid medications under the new Cannabis Act.

“Canntab is thrilled to see continued momentum on development of our oral extended release formulation. We’re confident that the license agreement with Emblem will help us to develop this product and to meet patients’ needs,” said Jeff Renwick, CEO, Canntab. “We look forward to the development of many potential markets for Canntab products, in part as a result of this significant milestone of Canntab’s.”

“Achieving this milestone marks a key step in the development of the oral extended release formulation,” said John H. Stewart, President, Emblem Medical. “The production of a reliable, long-acting formulation is complex and often very difficult to achieve. The results of the dissolution study signal that we will proceeding to the next stages of the product’s development with Canntab.”

Canntab’s Extended Release Tablets are designed to release cannabinoids over a period of 12 hours, which will provide patients with long-lasting effect without the need for multiple doses. Extended release medical products can be particularly valuable in the treatment of chronic conditions, such as chronic pain, where patients tend to require repeated dosing to obtain ongoing relief.

“Emblem’s strength in developing advanced formulations of cannabis for the medical market is further solidified by achievement of this major milestone. We believe the oral extended release formulation will be a game-changer in the medical cannabis market and that Emblem, through its license agreement with Canntab, is at the forefront of this development” said Nick Dean, CEO, Emblem Corp. “Precise, dose-controlled cannabis medications are critical to the acceptance of cannabis among prescribers and patients. Emblem has long been a medical-first LP and our foremost commitment is to patients. Innovative cannabis products for both the medical and adult-use space are fundamental to our long-term strategy, alongside brand building and distribution.”

The agreement between Emblem and Canntab calls for Emblem to make payments to Canntab upon achievement of certain milestones involving dissolution studies, bio-availability studies and regulatory approval of the Extended Release Product. As part of this milestone achievement, Emblem has made the required milestone payment to Canntab as a result of this significant achievement.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis! Canntab trades on the Canadian Securities Exchange under the symbol PILL.

About Emblem

Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

For further information contact:

Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

Emblem Corp.
Ethan Karayannopoulos
Investor Relations
+1 647.748.9696
ethank@emblemcorp.com

Alex Stojanovic
Chief Financial Officer
+1 416.923.1331
alexs@emblemcorp.com

Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation. 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *